Private equity interest in healthcare practices (dental, medical, and veterinary) has grown substantially over the past decade. For practice owners evaluating a sale or partnership with a PE-backed platform, the opportunity can appear compelling: meaningful upfront liquidity, operational infrastructure, and the possibility of additional upside if the platform exits at a higher valuation.

But these transactions are not ordinary practice sales. They involve deal structures, post-closing obligations, and regulatory considerations that can materially affect both the seller’s economics and professional flexibility long after closing.

What follows is not an argument against private equity transactions. It is a framework for evaluating and negotiating them with clarity.

The Structure Is Not Neutral

Most private equity acquisitions of healthcare practices involve some combination of upfront cash, rolled equity in the acquiring platform, and earnout provisions tied to post-closing performance. Each component carries a different risk profile, and sellers should understand the distinction before agreeing to terms.

Upfront cash is the most certain element. Rolled equity is not. Its value depends on the future performance and eventual exit of the PE platform, and if the platform underperforms, takes on excessive leverage, or is sold at a lower multiple than projected, the rolled equity may return significantly less than the seller anticipated. Treating rolled equity as equivalent to cash in present-value terms is an assumption the transaction does not support.

Earnouts introduce additional complexity. They tie a portion of the purchase price to future performance metrics such as production, collections, EBITDA, or other financial benchmarks, and the conditions governing those metrics are often more consequential than the amount itself. If the platform makes post-closing changes to staffing, scheduling, billing practices, or payer strategy, those decisions can affect the seller’s ability to hit the target. Sellers should focus on what they control after closing, not just what the earnout is worth on paper.

MSO Structures and Corporate Practice Restrictions

PE-backed acquisitions of healthcare practices are frequently structured to navigate state corporate practice of medicine, dentistry, or veterinary medicine restrictions. These laws vary by state and profession, but in general they may limit the ability of non-licensed entities to own or control a professional practice.

The structure most commonly used is the Management Services Organization, or MSO model. In a typical MSO structure, the PE-backed buyer acquires or controls the non-clinical assets and administrative infrastructure of the practice. A professional entity, owned by the licensed practitioner, retains clinical operations. The MSO then provides management and administrative services to the professional entity under a long-term management services agreement.

This framework is well established across the industry. But the terms of the management services agreement matter significantly. That document governs the economic relationship between the MSO and the professional entity for years after closing. It typically addresses management fees, renewal and termination rights, administrative control, staffing, billing support, branding, and other operational issues. Sellers who treat the MSA as secondary paperwork often find, well after closing, that it defined the transaction more than the purchase price did.

Because corporate practice restrictions are state-specific and profession-specific, sellers should confirm that the proposed structure has been properly analyzed under the laws applicable to their situation. A structure that functions in one state may require modification in another.

Representations, Warranties, and Post-Closing Exposure

Private equity purchase agreements typically require sellers to make extensive representations and warranties about the practice, like covering financial statements, billing and coding, payer relationships, employment matters, contracts, licenses, compliance, and the general condition of the business.

These provisions create real post-closing exposure. A representation that turns out to be inaccurate, even unintentionally, may give the buyer a claim for indemnification, subject to the negotiated procedures and limitations in the agreement. In some transactions, representation and warranty insurance shifts part of that risk. In smaller transactions, indemnification obligations may run directly against the seller and survive closing for negotiated periods.

The practical implication is that sellers should conduct meaningful pre-signing diligence on their own practice before making these representations. That review is particularly important for billing, coding, referral relationships, payer arrangements, and regulatory compliance. A seller who represents the practice as compliant without first examining the underlying operations is accepting exposure that has not been fully measured.

Healthcare private equity agreements commonly include representations relating to federal and state healthcare laws governing fraud and abuse, billing, licensure, payer participation, and referral-related rules. The relevance of particular laws will depend on the profession, payer mix, referral relationships, and transaction structure. Those provisions should be evaluated against actual operations, not treated as boilerplate.

Restrictive Covenants Can Be More Limiting Than Sellers Expect

Non-compete and non-solicitation provisions in PE transactions are frequently broader in scope and longer in duration than those seen in physician-to-physician or dentist-to-dentist deals. PE buyers are acquiring goodwill, patient relationships, and workforce stability as core components of what they paid for, and the covenants they require reflect that.

The practical effect on sellers can be significant. A multi-year non-compete combined with restrictions on soliciting patients, employees, or referral sources can materially constrain where and how a seller practices after closing.

Enforceability is state-specific and context-specific. Some states impose meaningful limitations on non-compete scope and duration, including in healthcare settings, and the rules may differ depending on whether the covenant arises from employment, ownership, or the sale of a business. In some jurisdictions, sale-of-business covenants may receive more latitude than ordinary employment covenants because the seller received substantial consideration for the goodwill being transferred. That treatment is not universal and should be evaluated under applicable state law.

Sellers should not assume that breadth equals unenforceability, and should not rely on that assumption as a substitute for careful negotiation. The better approach is to negotiate scope, duration, geography, and carve-outs deliberately before signing, when leverage to do so is highest.

The Valuation Gap Between Headline Price and Practical Economics

PE buyers typically value practices using EBITDA multiples, and in active markets those multiples can appear attractive. But the EBITDA figure driving the purchase price is often a normalized, adjusted number, and the adjustments used to produce it deserve scrutiny.

Adjustments may account for owner compensation, non-recurring expenses, related-party arrangements, staffing assumptions, or facility costs. Some are well-supported. Others are more aggressive. Sellers should understand exactly how adjusted EBITDA is being calculated before relying on a headline multiple, because a high multiple applied to an aggressively normalized earnings figure may reflect expectations the practice cannot realistically sustain after closing.

That gap matters beyond the closing date. It can affect earnout performance, platform stability, and the value of any equity the seller retains. Even where upfront cash is significant, the ongoing economics of the platform remain consequential if part of the seller’s consideration depends on what happens next.

Leverage Is Highest Before the LOI Is Signed

One of the most consistent patterns in PE healthcare transactions is that sellers bring in experienced advisors too late.

At the pre-LOI stage, the seller’s leverage is at its peak. Purchase price structure, rollover percentage, earnout design, MSA terms, restrictive covenant scope, and closing conditions are frequently framed, and sometimes effectively set, in the letter of intent. Once the LOI is signed, exclusivity typically begins, the buyer’s diligence process is underway, and the practical ability to revisit core terms diminishes.

Before engaging seriously with a PE-backed buyer or platform, sellers should review the proposed deal structure, including the allocation among cash, rolled equity, and earnout, and understand which entity controls which assets and economics after closing. Pre-signing diligence on billing, compliance, payer arrangements, employment matters, and financial statements should be completed before representations are made, not after. Restrictive covenant terms should be evaluated and negotiated early. And the EBITDA figure supporting the valuation should be examined with the same discipline a sophisticated buyer would apply to it.

Sellers who engage advisors at the LOI stage or later are often managing a structure that has already been largely defined. The most effective time to identify structural concerns and negotiate meaningful protections is before the seller has committed to a buyer, a timeline, and a set of headline economics.

Contact Morgan Advisory Group

Morgan Advisory Group advises physicians, dentists, veterinarians, and healthcare practice owners on transactions involving private equity, DSO and MSO platforms, and professional transitions. The firm brings legal knowledge and sophisticated business judgment to bear on complex healthcare transactions, from initial evaluation through closing and post-closing obligations.

If you are considering a PE transaction or evaluating interest from a platform, early advisory involvement is among the most effective ways to protect both value and leverage. Contact Morgan Advisory Group to schedule a confidential consultation.